Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study

  • Authors:
    • Jian Wang
    • Jingping Yu
    • Jianlin Wang
    • Xinchu Ni
    • Zhiqiang Sun
    • Wei Sun
    • Suping Sun
    • Yuting Lu
  • View Affiliations

  • Published online on: May 14, 2019     https://doi.org/10.3892/ol.2019.10354
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the efficiency and safety of a combination of thalidomide and chemo‑radiotherapy (CRT) for treating esophageal cancer (EC). Eligible patients received two cycles of chemotherapy using paclitaxel liposome and cisplatin concurrently with three‑dimensional radiotherapy. Following radiotherapy, two cycles of maintenance chemotherapy were performed. Patients with elevation of vascular endothelial growth factor (VEGF) during radiotherapy were randomly divided into: i) a test group (n=31), who received a combination of CRT and thalidomide; and ii) a control group (n=30), who received CRT only. Patients with locally advanced EC in the test group demonstrated a significantly improved 3‑year overall survival (OS) rate, progression‑free survival (PFS) rate, local control and median PFS time compared with the control group (P<0.05). Multivariate analysis indicated that Tumor‑Node‑Metastasis (TNM) stage was associated with the OS time, while TNM stage and the residence of cancer cells following radiotherapy were associated with PFS time. The present data indicate that thalidomide contributes to an improvement of prognosis for patients with locally advanced EC with elevated serum VEGF levels during radiotherapy. In addition, the toxicities induced by thalidomide were demonstrated to be tolerable.

Related Articles

Journal Cover

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Wang, J., Yu, J., Wang, J., Ni, X., Sun, Z., Sun, W. ... Lu, Y. (1899). Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study. Oncology Letters, 0, 0-0. https://doi.org/10.3892/ol.2019.10354
MLA
Wang, J., Yu, J., Wang, J., Ni, X., Sun, Z., Sun, W., Sun, S., Lu, Y."Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study". Oncology Letters 0.0 (1899): 0-0.
Chicago
Wang, J., Yu, J., Wang, J., Ni, X., Sun, Z., Sun, W., Sun, S., Lu, Y."Thalidomide combined with chemo‑radiotherapy for treating esophageal cancer: A randomized controlled study". Oncology Letters 0, no. 0 (1899): 0-0. https://doi.org/10.3892/ol.2019.10354